Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Kavalerchik

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2008
Chronic myeloid leukemia stem cellsEdward Kavalerchik, Daniel Goff, Catriona H M Jamieson
Blood|September 10, 2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaMichael Wang, Tom Martin, William Bensinger, et al.
Leukemia & Lymphoma|February 21, 2015
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myelomaRavi Vij, Michael Wang, Sundar Jagannath, et al.
Cancer Cell|April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitorsIfat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2008
Chronic myeloid leukemia stem cellsEdward Kavalerchik, Daniel Goff, Catriona H M Jamieson
Blood|September 10, 2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaMichael Wang, Tom Martin, William Bensinger, et al.
Leukemia & Lymphoma|February 21, 2015
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myelomaRavi Vij, Michael Wang, Sundar Jagannath, et al.
Cancer Cell|April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitorsIfat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Pageof 1